Filtered By:
Condition: Multiple Sclerosis
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 1656 results found since Jan 2013.
Microbiota, diet and the gut-brain axis in multiple sclerosis and acute stroke
This article is protected by copyright. All rights reserved.PMID:37470461 | DOI:10.1002/eji.202250229
Source: European Journal of Immunology - July 20, 2023 Category: Allergy & Immunology Authors: Laura Diaz-Marugan Johan B Kantsj ö Andrina Rutsch Francesca Ronchi Source Type: research
Telephone assistance for neurological diseases: a systematic review
CONCLUSIONS: Dementias are the diseases with more bibliographic references on their telephone assistance despite not being the most prevalent. The telephone is frequently used to administer diagnostic scales or support caregivers and is particularly useful in diseases that limit mobility and attending a medical practice.PMID:37466132 | DOI:10.33588/rn.7703.2022284
Source: Revista de Neurologia - July 19, 2023 Category: Neurology Authors: J M Trejo-Gabriel-Gal án E Cubo-Delgado Source Type: research
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Validity of 2 Fall Prevention Strategy Scales for People With Stroke, Parkinson's Disease, and Multiple Sclerosis: Erratum
J Geriatr Phys Ther. 2023 Jul-Sep 01;46(3):182. doi: 10.1519/JPT.0000000000000390.NO ABSTRACTPMID:37404135 | DOI:10.1519/JPT.0000000000000390
Source: Physical Therapy - July 5, 2023 Category: Physiotherapy Source Type: research
Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL): A challenging diagnosis and a rare multiple sclerosis mimic
Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is an extremely rare hereditary cerebral small vessel disease caused by homozygous or compound heterozygous mutations in the gene coding for high-temperature requirement A serine peptidase 1 (HtrA1). Given the rare nature of the disease, delays in diagnosis and misdiagnosis are not uncommon. In this article, we reported the first case of CARASIL from Saudi Arabia with a novel homozygous variant c.1156C>T in exon 7 of the HTRA1 gene.
Source: Journal of Stroke and Cerebrovascular Diseases - June 20, 2023 Category: Neurology Authors: Bader Shirah, Hussein Algahtani, Raghad Algahtani, Ahmed Alfares, Ahmed Hassan Tags: Case Report Source Type: research
Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion
Transl Stroke Res. 2023 Jun 16. doi: 10.1007/s12975-023-01164-2. Online ahead of print.ABSTRACTRepulsive guidance molecule A (RGMa) is an inhibitor of neuronal growth and survival which is upregulated in the damaged central nervous system following acute spinal cord injury (SCI), traumatic brain injury, acute ischemic stroke (AIS), and other neuropathological conditions. Neutralization of RGMa is neuroprotective and promotes neuroplasticity in several preclinical models of neurodegeneration and injury including multiple sclerosis, AIS, and SCI. Given the limitations of current treatments for AIS due to narrow time windows ...
Source: Cell Research - June 16, 2023 Category: Cytology Authors: Peer B Jacobson Andrea Mothe Aharon Levy Michael Krakovsky Bradley A Hooker Xiaomeng Zhang Jennifer Mollon Yulia Mordashova Mathias Droescher Sabine Weiss Stefan Barghorn Ingeborg Dreher Khader Awwad Volker Nimmrich Lili Huang Emma Fung Wayne R Buck Kimbe Source Type: research
Validity, reliability and minimal detectable change of Mini-BESTest Turkish version in neurological disorders
ConclusionsMini-BESTestTR showed significant correlations with other balance assessment measures, and concurrent and convergent validity of Mini-BESTestTR was demonstrated when administered to a sample of patients with chronic stroke, Parkinson ’s disease and multiple sclerosis.
Source: Acta Neurologica Belgica - June 16, 2023 Category: Neurology Source Type: research
